Nylidrin hydrochloride | CAS#849-55-8 | beta-adrenergic agonist

MedKoo Cat#: 592951 | Name: Nylidrin hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nylidrin hydrochloride is a beta-adrenergic agonist. Nylidrin hydrochloride is shown to be an effective inhibitor of IgE-mediated release of histamine from human basophils, and thus can be used as antiallergic agent. It is also one of the FDA approved drug as Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP).

Chemical Structure

Nylidrin hydrochloride

CAS#849-55-8

Theoretical Analysis

MedKoo Cat#: 592951

Name: Nylidrin hydrochloride

CAS#: 849-55-8

Chemical Formula: C19H26ClNO2

Exact Mass: 335.1652

Molecular Weight: 335.87

Elemental Analysis: C, 67.95; H, 7.80; Cl, 10.55; N, 4.17; O, 9.53

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 500.00
250mg	USD 650.00
500mg	USD 975.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Nylidrin hydrochloride; Arlidin; Arlidin Hydrochloride; Bufedon; Buphedrin; Buphenine Hydrochloride; Dilatal; Dilatol; Dilatol Hydrochloride; Dilatropon; Dilydrin;

IUPAC/Chemical Name

Benzenemethanol, 4-hydroxy-alpha-(1-((1-methyl-3-phenylpropyl)amino)ethyl)-, hydrochloride

InChi Key

CLJHABUMMDMAFA-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H25NO2.ClH/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17;/h3-7,10-15,19-22H,8-9H2,1-2H3;1H

SMILES Code

OC(C(NC(C)CCC1=CC=CC=C1)C)C2=CC=C(O)C=C2.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Nylidrin hydrochloride was an effective inhibitor of IgE-mediated release of histamine from passively sensitized rat peritoneal mast cells and human basophils, and of IgG1-mediated release of histamine from passively sensitized guinea pig lung slices.

In vitro activity:

Nylidrin-induced elevation of cellular cAMP in purified rat mast cells shows no correlation with nylidrin-induced inhibition of histamine release. Thus, nylidrin hydrochloride inhibits release of histamine from mast cells by a novel, non-adrenergic mechanism, which is not dependent on increased levels of cAMP. Reference: Int Arch Allergy Appl Immunol. 1983;70(4):303-10. https://pubmed.ncbi.nlm.nih.gov/6186609/

In vivo activity:

Body weight changes and survival rates confirmed that nylidrin not only mitigated body weight loss induced by viral infection (Figure 5A), but also prevented mortality: complete survival (100%) was comparable to that in the OSV-P-treated group (Figure 5B). In contrast, mice infected with the vehicle-treated maPR8 died between days 9 and 11. Taken together, these findings suggest that nylidrin protects mice from viral infection in vivo by directly targeting the HA2 function of influenza A virus (H1N1). Reference: Viruses. 2020 May 25;12(5):581. https://pubmed.ncbi.nlm.nih.gov/32466302/

	Solvent	mg/mL	mM
Solubility
	DMSO	45.5	135.47
	Water	5.0	14.89

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 335.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Coutts SM, Khandwala A, Weinryb I. Antiallergic activity of nylidrin hydrochloride (RHC 3432-A). II. A lack of correlation between inhibition of mediator release and levels of cyclic AMP. Int Arch Allergy Appl Immunol. 1983;70(4):303-10. PMID: 6186609. 2. Khandwala A, Coutts SM, Weinryb I. Antiallergic activity of nylidrin hydrochloride (RHC 3432-A). I. Effect on release of histamine in vitro from rat peritoneal mast cells, guinea pig lung slices and human basophils. Int Arch Allergy Appl Immunol. 1983;70(4):295-302. PMID: 6186608. 3. Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581. PMID: 32466302; PMCID: PMC7290441.

In vitro protocol:

In vivo protocol:

1. Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581. PMID: 32466302; PMCID: PMC7290441.

1: Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020 Oct 16;10(10):CD005262. doi: 10.1002/14651858.CD005262.pub4. PMID: 33063850; PMCID: PMC8094235. 2: Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581. PMID: 32466302; PMCID: PMC7290441. 3: Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015 Sep 29;9(9):CD005262. doi: 10.1002/14651858.CD005262.pub3. Update in: Cochrane Database Syst Rev. 2020 Oct 16;10:CD005262. doi: 10.1002/14651858.CD005262.pub4. PMID: 26417854; PMCID: PMC6513423. 4: Awan KH, Patil S, Habib SR, Pejcic A, Zain RB. Evaluation of medicinal interventions for the management of oral submucous fibrosis: a systematic review of the literature. J Contemp Dent Pract. 2014 Nov 1;15(6):812-7. doi: 10.5005/jp-journals-10024-1623. PMID: 25825114. 5: Montijo-Barrios E, Cadena F, Ramírez-Mayans JA, Gutiérrez-Castrellón P. Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad [Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age]. Rev Invest Clin. 2011 Jul-Aug;63(4):335-43. Spanish. PMID: 22364032. 6: Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhore SV, Ghonmode S, Balwani S, Mankar M, Tiwari M, Parikh RV. Review of drug treatment of oral submucous fibrosis. Oral Oncol. 2012 May;48(5):393-8. doi: 10.1016/j.oraloncology.2011.11.021. Epub 2011 Dec 27. PMID: 22206808. 7: Bartlett H, Eperjesi F. Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. Ophthalmic Physiol Opt. 2003 Sep;23(5):383-99. doi: 10.1046/j.1475-1313.2003.00130.x. PMID: 12950886. 8: Höfner G, Wanner KT. [3H]ifenprodil binding to NMDA receptors in porcine hippocampal brain membranes. Eur J Pharmacol. 2000 Apr 14;394(2-3):211-9. doi: 10.1016/s0014-2999(00)00084-4. PMID: 10771286. 9: Brambilla G, Fiori M, Curiel I, Serpe L, Gallo P. Alpha 1-acid glycoprotein affinity columns for the clean-up of adrenergic drugs. Analyst. 1998 Dec;123(12):2693-6. doi: 10.1039/a806218h. PMID: 10435325. 10: Tamiz AP, Whittemore ER, Zhou ZL, Huang JC, Drewe JA, Chen JC, Cai SX, Weber E, Woodward RM, Keana JF. Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D- aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. doi: 10.1021/jm980235+. PMID: 9719603. 11: Whittemore ER, Ilyin VI, Konkoy CS, Woodward RM. Subtype-selective antagonism of NMDA receptors by nylidrin. Eur J Pharmacol. 1997 Oct 22;337(2-3):197-208. doi: 10.1016/s0014-2999(97)01292-2. PMID: 9430414. 12: Pahk AJ, Williams K. Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett. 1997 Mar 28;225(1):29-32. doi: 10.1016/s0304-3940(97)00176-6. PMID: 9143010. 13: Salokorpi T, Eronen M, von Wendt L. Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin. Neuropediatrics. 1996 Aug;27(4):174-7. doi: 10.1055/s-2007-973782. PMID: 8892364. 14: Kaiser HJ, Flammer J, Stümpfig D, Hendrickson P. Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica. 1995;209(6):302-5. doi: 10.1159/000310646. PMID: 8751336. 15: Eronen M, Pesonen E, Kurki T, Teramo K, Ylikorkala O, Hallman M. Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. J Pediatr. 1994 May;124(5 Pt 1):782-8. doi: 10.1016/s0022-3476(05)81374-5. PMID: 8176569. 16: Mercer LD, Jarrott B, Beart PM. 125I-ifenprodil: synthesis and characterization of binding to a polyamine-sensitive site in cerebral cortical membranes. J Neurochem. 1993 Jul;61(1):120-6. doi: 10.1111/j.1471-4159.1993.tb03545.x. PMID: 8515257. 17: Eronen M. The hemodynamic effects of antenatal indomethacin and a beta- sympathomimetic agent on the fetus and the newborn: a randomized study. Pediatr Res. 1993 Jun;33(6):615-9. doi: 10.1203/00006450-199306000-00017. PMID: 8378121. 18: Kurki T, Viinikka L, Ylikorkala O. Urinary excretion of prostacyclin and thromboxane metabolites in threatened preterm labor: effect of indomethacin and nylidrin. Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):150-4. doi: 10.1016/0002-9378(92)91851-z. PMID: 1733190. 19: Spindler E, Janier M, Bonnin JM, Carlotti A, Daniel F. Pustulose exanthématique aiguë généralisée liée à la buphénine: un cas [Generalized exanthematous pustulosis caused by buphenine: report of a case]. Ann Dermatol Venereol. 1992;119(4):273-5. French. PMID: 1388340. 20: Kurki T, Eronen M, Lumme R, Ylikorkala O. A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm labor. Obstet Gynecol. 1991 Dec;78(6):1093-7. PMID: 1945214.